Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study von Oing, C., Oechsle, K., Necchi, A., Loriot, Y., De Giorgi, U., Fléchon, A., Daugaard, G., Fedyanin, M., Faré, E., Bokemeyer, C.

Volltext

Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase... von Giannatempo, P., Raggi, D., Marandino, L., Bandini, M., Farè, E., Calareso, G., Colecchia, M., Gallina, A., Ross, J.S., Alessi, A., Briganti, A., Montorsi, F., Madison, R., Necchi, A.

Volltext

Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes von Giannatempo, P., Greco, T., Mariani, L., Nicolai, N., Tana, S., Farè, E., Raggi, D., Piva, L., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Avuzzi, B., Maffezzini, M., Landoni, G., De Braud, F., Gianni, A.M., Sonpavde, G., Salvioni, R., Necchi, A.

Volltext

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-grou... von Necchi, A., Giannatempo, P., Mariani, L., Farè, E., Raggi, D., Pennati, M., Zaffaroni, N., Crippa, F., Marchianò, A., Nicolai, N., Maffezzini, M., Togliardi, E., Daidone, M. G., Gianni, A. M., Salvioni, R., De Braud, F.

Volltext

Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognost... von Necchi, A, Pennati, M, Zaffaroni, N, Landoni, E, Giannatempo, P, Raggi, D, Schwartz, L H, Morosi, C, Crippa, F, Farè, E, Nicolai, N, Lanocita, R, Sava, T, Sacco, C, Messina, C, Ortega, C, De Braud, F G, Salvioni, R, Daidone, M G, Gianni, A M, Mariani, L

Volltext

Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes von Necchi, A., Nicolai, N., Mariani, L., Raggi, D., Farè, E., Giannatempo, P., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Milani, A., Piva, L., Pizzocaro, G., Gianni, A.M., Salvioni, R.

Volltext

High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized ph... von Necchi, A., Mariani, L., Di Nicola, M., Lo Vullo, S., Nicolai, N., Giannatempo, P., Raggi, D., Farè, E., Magni, M., Piva, L., Matteucci, P., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Bengala, C., Barone, C., Schiavetto, I., Siena, S., Carlo-Stella, C., Pizzocaro, G., Salvioni, R., Gianni, A.M.

Volltext

Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem? von Farè, E., Sdao, S., Damian, S., Cresta, S., Del Vecchio, M., Di Bartolomeo, M., Di Guardo, L.A., Duca, M., Indini, A., Necchi, A., Niger, M., Prisciandaro, M., Procopio, G., Raggi, D., Verzoni, E., Pruneri, G., Di Nicola, M., de Braud, F.G.M.

Volltext

Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: evaluation of safety and efficacy of open and laparoscopic procedures von Nicolai, N., Nazzani, S., Catanzaro, M., Tesone, A., Macchi, A., Torelli, T., Stagni, S., Celso, F., Agostini, E., Cloecchia, M., Avuzzi, B., Lanocita, R., Necchi, A., Raggi, D., Giannatempo, P., Farè, E., Salvioni, R., Biasoni, D.

Volltext

Interim results of PEANUT: An open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for meta... von Necchi, A., Raggi, D., Bandini, M., Farè, E., Giannatempo, P., Colecchia, M., Pederzoli, F., Gallina, A., Marandino, L., Calareso, G., Madison, R., Briganti, A., Ross, J., Montorsi, F.

Volltext

Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasiv... von Necchi, A., Raggi, D., Briganti, A., Farè, E., Giannatempo, P., Marandino, L., Gallina, A., Colecchia, M., Lucianò, R., Bianchi, M., Colombo, R., Salonia, A., Gandaglia, G., Fossati, N., Capitanio, U., Montorsi, F., Boormans, J., Liu, Y., De Jong, J., Dittamore, R., Davicioni, E., Black, P., Gibb, E.

Volltext

2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC) von Bottiglieri, A., Ferrari Bravo, W., Rametta, A., Provenzano, L., Raggi, D., Marandino, L., Farè, E., Longo, V., Guadalupi, V., Stellato, M., Verzoni, E., Sepe, P., Claps, M., Calareso, G., Alessi, A., Cattaneo, L., Colecchia, M., Procopio, G., Necchi, A., Giannatempo, P.

Volltext

1116 Is template laparoscopic retroperitoneal lymph-node disection (Lap-RPLND) an advisable option for adequately selected patients with a residual mass of non-seminomatous germ-ce... von Nicolai, N, Stagni, S, Biasoni, D, Catanzaro, M, Crestani, A, Colecchia, M, Torelli, T, Piva, L, Maffezzini, M, Necchi, A, Giannatempo, P, Faré, E, Salvioni, R

Volltext

57 Neo-adjuvant and adjuvant combination of a taxane plus cisplatin and 5-fluorouracil in patients undergoing lymph-node dissection for nodal metastases from squamous cell carcinom... von Nicolai, N, Sangalli, L.M, Necchi, A, Giannatempo, P, Paganoni, A.M, Colecchia, M, Piva, L, Catanzaro, M, Biasoni, D, Stagni, S, Torelli, T, Raggi, D, Faré, E, Crestani, A, Pizzocaro, G, Salvioni, R

Volltext

Wooden breast disease in commercial broiler chickens: A histologic and RNA sequencing study von Fare, E L, Babak, M P, Abasht, B

Volltext

049 Wooden breast disease in commercial broiler chickens: A histologic and RNA sequencing study von Fare, E. L., Babak, M. P., Abasht, B.

Volltext

913PD - APACHE: An open label, randomized, phase II study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with refractory germ cell tumo... von Farè, E., Raggi, D., Giannatempo, P., Colecchia, M., Calareso, G., Ali, S.M., Chung, J., Ross, J.S., Necchi, A.

Volltext

913PDAPACHE: An open label, randomized, phase II study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with refractory germ cell tumours... von Farè, E, Raggi, D, Giannatempo, P, Colecchia, M, Calareso, G, Ali, S M, Chung, J, Ross, J S, Necchi, A

Volltext

APACHE: An open label, randomized, phase II study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with refractory germ cell tumours (GCT... von Farè, E., Raggi, D., Giannatempo, P., Colecchia, M., Calareso, G., Ali, S.M., Chung, J., Ross, J.S., Necchi, A.

Volltext

37INIs "hyper-progression" a relevant clinical item for patient with solid tumours candidate to check-point inhibitor treatment? von de Braud, F, Di Nicola, M, Damian, S, Cresta, S, Duca, M, Indini, A, Di Bartolomeo, M, Galli, G, Farè, E, Verzoni, E

Volltext